A Single-dose, Randomized, Three-period, Crossover Comparative Bioavailability Study of a Novel Formulation of Aripiprazole 10 mg Oral Soluble Film vs the Marketed Formulation Abilify 10 mg Tablet in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 30 Mar 2016
At a glance
- Drugs Aripiprazole (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors CMG Pharmaceutical
- 23 Mar 2016 Protocol amended as treatment arms changed from 1 to 3, study design changed from single group to crossover assignment as reported by ClinicalTrials.gov.
- 23 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Oct 2015 Planned End Date changed from 1 Dec 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov record.